Journal of Neuroinfectious Diseases
Open Access

Zika Virus; Central Nervous System; Neuropathogenesis; Congenital Zika Syndrome; Neuroinflammation; Guillain-Barré Syndrome; Microcephaly; Neural Stem Cells; Blood-Brain Barrier; Neuroimaging

Introduction

The Zika virus (ZIKV) represents a considerable global health concern due to its profound impact on the central nervous system (CNS), manifesting in a range of neurological disorders affecting both adults and infants. In adults, ZIKV infection can precipitate severe conditions such as meningoencephalitis, myelitis, and Guillain-Barré syndrome, underscoring the virus's neuroinvasive capabilities. For infants born to mothers infected during pregnancy, the consequences can be particularly devastating, leading to congenital Zika syndrome, a condition characterized by microcephaly, intracranial calcifications, and significant developmental abnormalities. The virus's ability to surmount the blood-brain barrier and subsequently infect neural progenitor cells and mature neurons is fundamental to its neuropathogenesis, making the CNS a primary target. Ongoing research endeavors are dedicated to unraveling the complex molecular and cellular mechanisms by which ZIKV induces neuroinflammation, damages neuronal structures, and results in persistent neurological deficits. Understanding these intricate pathways is essential for the development of effective therapeutic and preventive strategies against ZIKV-induced neurological diseases. The exploration into how ZIKV infiltrates the CNS and disrupts neuronal function continues to be a critical area of investigation, aiming to mitigate the long-term neurological sequelae observed in affected populations. The direct attack on neural cells and the ensuing inflammatory responses highlight the virus's potent neurovirulence. The scientific community is committed to advancing knowledge in this field to combat the widespread neurological impact of ZIKV infections. The persistent threat posed by ZIKV necessitates continued vigilance and research into its complex interactions with the human nervous system. The spectrum of neurological manifestations, from acute syndromes to chronic impairments, demands a comprehensive understanding of the viral pathogenesis within the CNS. The implications for public health, particularly in regions where ZIKV is endemic, are substantial and require targeted interventions based on scientific evidence. This review aims to synthesize current knowledge on ZIKV's neuropathogenesis, drawing from a wide array of research findings to provide a holistic perspective on its impact. The critical need for developing treatments and preventative measures is driven by the severe and often irreversible neurological damage associated with ZIKV infection. [1] The pathogenesis of Zika virus infection within the developing brain is intricately linked to the virus's capacity to directly infect neural stem cells (NSCs) and progenitor cells, which are vital for brain development. ZIKV significantly disrupts the normal processes of neurogenesis, leading to a marked reduction in the population of both neurons and glial cells, the fundamental building blocks of the nervous system. This cellular dysfunction, compounded by the host's inflammatory responses, is a primary contributor to the characteristic microcephaly and other profound brain malformations observed in infants suffering from congenital Zika syndrome. Elucidating how ZIKV adeptly evades the nascent immune responses in the developing fetus and specifically targets developing neural cells is paramount for the formulation of effective preventative measures and novel therapeutic interventions. The vulnerability of the fetal brain to ZIKV infection underscores the critical need for robust public health strategies aimed at preventing maternal exposure and managing infected pregnancies. The early stages of brain development are particularly susceptible to the detrimental effects of ZIKV, leading to long-lasting developmental deficits. Research is focused on understanding the molecular targets of ZIKV within these developing neural cells. The interplay between viral replication and host cellular machinery in the developing brain presents a complex challenge for therapeutic intervention. Understanding the precise mechanisms of ZIKV entry and replication in these critical cells is a priority for research. The observed reduction in neuronal and glial cell populations has direct implications for cognitive and motor functions. The immune system's response, or lack thereof, in the developing brain plays a crucial role in determining the severity of ZIKV-induced damage. Strategies aimed at protecting neural progenitor cells from viral infection are actively being investigated. The long-term consequences of disrupted neurogenesis can manifest in various neurodevelopmental disorders. [2] In adult populations, Zika virus infection has the potential to trigger an autoimmune response that specifically targets the peripheral nervous system, most notably leading to the development of Guillain-Barré syndrome (GBS). A leading hypothesis for this autoimmune cross-reactivity involves molecular mimicry, where viral epitopes bear a striking resemblance to host neuronal antigens, thereby misleading the immune system to attack the body's own tissues. Furthermore, the neuroinflammatory cascade initiated by ZIKV infection can extend its reach to affect the spinal cord and brainstem, resulting in clinical manifestations consistent with myelitis and encephalitis. Ongoing research efforts are actively engaged in identifying the specific viral components or antigens that are responsible for triggering these complex immune-mediated neurological complications. This understanding is crucial for developing targeted immunotherapies that can mitigate the autoimmune attack without compromising essential immune functions. The identification of specific viral epitopes involved in molecular mimicry is a key area of focus for vaccine development and therapeutic strategies. The intricate relationship between viral infection and autoimmune responses highlights the complex interplay between the pathogen and the host's immune system. The clinical presentation of GBS following ZIKV infection emphasizes the systemic impact of the virus beyond direct neuronal damage. Research into the underlying mechanisms of ZIKV-induced autoimmunity is vital for predicting and preventing neurological sequelae. The potential for cross-reactivity with host antigens presents a significant challenge in developing safe and effective treatments. Investigating the genetic and environmental factors that predispose individuals to developing GBS after ZIKV infection is also an area of interest. The long-term prognosis for adults with ZIKV-associated GBS varies, necessitating continued follow-up and supportive care. [3] A significant aspect of ZIKV's neuropathogenesis is the documented persistence of Zika virus RNA and viral proteins within the CNS, including the brain and cerebrospinal fluid, even after the acute phase of infection has seemingly resolved. This prolonged presence of viral material within the neural environment is strongly implicated as a contributing factor to the long-term neurological sequelae experienced by some individuals, which can include persistent cognitive deficits and sensory impairments. Advanced research methodologies, such as cutting-edge imaging techniques and detailed molecular analyses, are continuously shedding light on the chronic effects that ZIKV exerts on neuronal function and overall brain structure. These findings underscore the importance of considering the long-term impact of ZIKV infection beyond the acute symptomatic period. The detection of viral RNA in the CNS suggests ongoing viral activity or the presence of viral reservoirs. Understanding the mechanisms by which ZIKV persists in the CNS is crucial for developing strategies to eradicate the virus. Chronic inflammation and neuronal dysfunction can result from this persistent viral presence. The implications of viral persistence for long-term neurological health are a critical area of ongoing study. Research into the clearance of ZIKV from the CNS is essential for preventing chronic neurological complications. The detection methods used to identify viral persistence are continually being refined. The impact of viral persistence on different types of neural cells is also being investigated. The long-term effects may vary depending on the route of infection and individual immune responses. [4] Zika virus exhibits a notable tropism for glial cells, including astrocytes and microglia, which are crucial supporting cells of the nervous system, in addition to its direct infection of neurons. The activation of these glial cells, particularly microglia, plays a pivotal role in exacerbating neuroinflammation and consequently, in amplifying neuronal damage. When microglia are activated by ZIKV, they release a cascade of pro-inflammatory cytokines, creating a highly detrimental environment that compromises neuronal survival and impedes the processes of neural repair. Consequently, a comprehensive understanding of the intricate interplay between ZIKV and these glial cell populations is deemed critical for the development of effective immunomodulatory therapies aimed at mitigating the detrimental effects of neuroinflammation. The role of glial cells in ZIKV pathogenesis is a key area for therapeutic intervention. Targeting microglial activation could offer a strategy to reduce neuroinflammation. The cytokines released by activated glial cells contribute to the neuronal damage observed in ZIKV infections. Astrocytes, another type of glial cell, are also affected by ZIKV and can contribute to the inflammatory milieu. Understanding the precise molecular signals that trigger glial cell activation by ZIKV is essential. The balance between pro-inflammatory and anti-inflammatory responses in the CNS is critical. Research into how ZIKV manipulates glial cell functions is ongoing. The potential for glial cells to act as reservoirs for ZIKV is also being explored. Strategies to modulate glial cell responses could lead to novel treatment approaches. [5] Congenital Zika syndrome is characterized by a multifaceted spectrum of brain abnormalities, extending beyond mere microcephaly to include other severe structural deficits. These abnormalities can encompass ventricular enlargement, significant cerebral cortical thinning, and malformations of the posterior fossa, all of which arise from ZIKV's profound disruption of critical processes during fetal brain development, including neuronal differentiation, migration, and overall growth. Prenatal exposure to ZIKV has been unequivocally linked to lasting cognitive and motor impairments that necessitate lifelong management and extensive support systems for affected children. The severity and type of brain malformations can vary widely depending on the timing and level of maternal viral exposure during pregnancy. Early detection and intervention are crucial for optimizing developmental outcomes in children with congenital Zika syndrome. The long-term impact on a child's quality of life underscores the importance of preventing ZIKV infections in pregnant women. Research continues to refine diagnostic criteria and identify predictors of developmental outcomes. The complex interplay of genetic and environmental factors may influence the manifestation of congenital Zika syndrome. Comprehensive care plans are essential to address the diverse needs of affected individuals. The identification of specific developmental milestones and potential interventions is an ongoing area of research. The societal and economic burden of congenital Zika syndrome is significant, highlighting the need for global health initiatives. [6] The blood-brain barrier (BBB), a highly selective physiological barrier, normally serves as a formidable defense mechanism protecting the CNS from pathogens and toxic substances. However, emerging evidence indicates that ZIKV possesses the capability to breach this crucial protective barrier through a variety of sophisticated mechanisms. These mechanisms may involve the direct infection of endothelial cells that constitute the BBB, or the virus may exploit cellular transport pathways to gain entry into the neural environment. Once ZIKV successfully enters the CNS, its potent neuropathogenic potential is unleashed through its ability to directly infect various neural cell types and to elicit a robust neuroinflammatory response. Understanding the precise molecular and cellular strategies ZIKV employs to overcome the BBB is a critical area of research for developing targeted prophylactic and therapeutic interventions. The breaching of the BBB by ZIKV is a key step in its neuroinvasion. Mechanisms of ZIKV entry into the CNS are complex and multifaceted. Direct infection of endothelial cells represents one potential route. Cellular transport mechanisms may also be involved in ZIKV's passage across the BBB. The BBB's integrity is compromised during ZIKV infection. Research aims to identify specific viral proteins or host factors involved in BBB penetration. The development of therapies to prevent or inhibit ZIKV entry into the CNS is a major goal. The consequences of BBB disruption can include increased inflammation and neuronal damage. The efficiency of ZIKV crossing the BBB may vary between individuals. [7] Neuroimaging studies conducted on adult patients diagnosed with ZIKV-associated neurological diseases have consistently revealed characteristic findings, offering valuable insights into the pathology. These findings often include the presence of T2-weighted hyperintensities, which indicate areas of inflammation or edema, predominantly observed in the white matter, basal ganglia, and brainstem. In more severe cases, particularly those involving encephalitis or myelitis, these hyperintensities are frequently accompanied by contrast enhancement, signifying active inflammation and breakdown of the BBB. These distinct imaging patterns correlate directly with the patients' clinical symptoms, providing a crucial link between the observable pathology and the patient's neurological presentation. Such findings are instrumental in the diagnosis, monitoring of disease progression, and evaluation of treatment efficacy in ZIKV-infected individuals. The characteristic imaging findings in adults with ZIKV infection aid in diagnosis. T2-weighted hyperintensities in specific brain regions are common. Contrast enhancement indicates active inflammation. Neuroimaging plays a vital role in understanding the extent of CNS involvement. These findings help correlate pathology with clinical symptoms. The patterns observed can guide treatment strategies. Longitudinal imaging studies are valuable for tracking disease progression. Advanced imaging techniques offer more detailed insights. The differentiation of ZIKV-induced lesions from other neurological conditions is aided by these findings. [8] Currently, the therapeutic landscape for addressing ZIKV-induced damage to the CNS remains notably limited, presenting a significant challenge in managing affected individuals. While certain antiviral drugs have demonstrated some degree of efficacy in preclinical animal models, their actual clinical utility in treating established neurological diseases in humans is still undergoing rigorous investigation and has not yet been definitively established. In parallel, immunomodulatory approaches that aim to dampen the excessive and often damaging neuroinflammatory responses triggered by ZIKV infection are also being actively explored as promising potential treatment strategies. The development of effective therapies is hampered by the complexity of ZIKV's interaction with the nervous system. Antiviral drug development for ZIKV is an ongoing area of research. Immunomodulatory therapies aim to control neuroinflammation. The limited therapeutic options highlight the urgent need for further research. Combination therapies, targeting both the virus and the inflammatory response, may be beneficial. Personalized medicine approaches could tailor treatments to individual patient profiles. The development of effective treatments is critical for improving patient outcomes. Research into neuroprotective strategies is also being pursued. The challenges in drug delivery to the CNS complicate treatment development. [9] The long-term neurological sequelae observed in children who were exposed to Zika virus in utero constitute a significant and ongoing public health concern, extending far beyond the initial diagnosis of microcephaly. These children can experience a wide spectrum of developmental challenges, including significant visual impairments, hearing loss, recurrent seizures, and substantial delays in cognitive and motor development. To gain a comprehensive understanding of the full spectrum of these enduring neurological effects and to develop appropriate, effective interventions and robust support systems, ongoing longitudinal studies are absolutely crucial. These studies are vital for tracking the developmental trajectories of affected children and for identifying the most effective strategies for optimizing their long-term health and well-being. The long-term impact of prenatal ZIKV exposure on children is a critical area of concern. Beyond microcephaly, a range of other neurodevelopmental issues can arise. Visual and hearing impairments are common. Seizures and developmental delays require specialized care. Longitudinal studies are essential for understanding the full scope of long-term effects. Developing effective interventions and support systems is paramount. Research focuses on early identification of potential problems. Improving the quality of life for affected children is a primary goal. The need for comprehensive, multidisciplinary care is evident. [10]

Description

The Zika virus (ZIKV) infection poses a serious threat to the central nervous system (CNS), leading to a variety of neurological disorders in both adults and infants. In adults, ZIKV can cause meningoencephalitis, myelitis, and Guillain-Barré syndrome, indicating its ability to affect the adult nervous system. In infants born to infected mothers, the most severe outcome is congenital Zika syndrome, characterized by microcephaly, brain calcifications, and developmental issues. The virus's capability to cross the blood-brain barrier and infect neural progenitor cells and mature neurons is key to its neuropathogenesis. Ongoing research is investigating the complex mechanisms of ZIKV-induced neuroinflammation, neuronal damage, and long-term neurological consequences. Understanding these processes is crucial for developing effective treatments and preventive measures. The ability of ZIKV to enter and damage the CNS highlights its neurovirulence. The spectrum of neurological problems underscores the importance of continued research into ZIKV's impact on the nervous system. The virus's interaction with neural cells and the resulting inflammation are central to its disease-causing mechanisms. The implications for public health are significant, particularly in areas where ZIKV is prevalent. [1] The pathogenesis of Zika virus in the developing brain involves the direct infection of neural stem cells (NSCs) and progenitor cells, which are essential for brain formation. ZIKV disrupts neurogenesis, resulting in a reduction in the number of neurons and glial cells, which are vital for brain function. This cellular damage, combined with inflammatory responses, contributes to the microcephaly and other brain malformations seen in congenital Zika syndrome. Understanding how ZIKV bypasses early immune defenses and targets developing neural cells is critical for developing preventive and therapeutic strategies. The developing brain's vulnerability to ZIKV infection emphasizes the need for strategies to prevent maternal exposure. The early stages of brain development are highly susceptible to ZIKV's damaging effects. Research is focused on identifying ZIKV's molecular targets in these developing cells. Disruptions in neurogenesis can lead to long-term developmental problems. The immune system's role in the developing brain during ZIKV infection is a complex area of study. Protecting neural progenitor cells from ZIKV is a key research objective. The consequences of altered neurogenesis can impact cognitive and motor abilities. [2] In adults, Zika virus can induce autoimmune responses that affect the peripheral nervous system, leading to Guillain-Barré syndrome (GBS). A proposed mechanism for this is molecular mimicry, where viral components resemble host neuronal antigens, triggering an immune attack on the body's own tissues. ZIKV infection can also cause neuroinflammation that impacts the spinal cord and brainstem, resulting in symptoms of myelitis and encephalitis. Research is actively seeking to identify the specific viral elements responsible for initiating these immune-mediated neurological complications. This knowledge is essential for developing targeted immunotherapies. The link between viral infection and autoimmune reactions highlights the intricate relationship between ZIKV and the human immune system. The occurrence of GBS following ZIKV infection demonstrates the virus's systemic effects beyond direct neural damage. Investigating the causes of ZIKV-induced autoimmunity is vital for predicting and preventing neurological problems. The possibility of cross-reactivity with host antigens poses a challenge for treatment development. Factors influencing the susceptibility to GBS after ZIKV infection are under study. The long-term outlook for adults with ZIKV-related GBS can vary, requiring ongoing medical attention. [3] A notable characteristic of ZIKV's impact on the CNS is the persistence of viral RNA and proteins in the brain and cerebrospinal fluid, even after the acute infection has resolved. This prolonged presence of viral material is thought to contribute to long-term neurological issues, including cognitive impairments and sensory deficits. Advanced research techniques, such as sophisticated imaging and molecular analyses, are providing deeper insights into the chronic effects of ZIKV on neuronal function and brain structure. These findings highlight the importance of considering the long-term health implications of ZIKV infection beyond the initial illness. The presence of viral RNA in the CNS suggests ongoing viral activity or the existence of viral reservoirs. Understanding how ZIKV persists in the CNS is crucial for preventing chronic neurological problems. Chronic inflammation and impaired neuronal function can result from persistent viral presence. The long-term consequences of sustained viral presence are a critical research focus. Efforts to clear ZIKV from the CNS are essential for averting chronic neurological complications. The methods used to detect viral persistence are continually being improved. The effects of viral persistence on different types of nerve cells are also being investigated. The long-term outcomes may differ based on the infection route and individual immune responses. [4] Zika virus targets glial cells, including astrocytes and microglia, in addition to neurons, playing a significant role in neuropathogenesis. The activation of these glial cells contributes to neuroinflammation, which worsens neuronal damage. ZIKV-induced microglial activation can lead to the release of pro-inflammatory cytokines, creating an environment hostile to neuronal survival and repair. Therefore, understanding the interaction between ZIKV and glial cells is crucial for developing immunomodulatory therapies to combat neuroinflammation. Glial cells are key players in ZIKV pathogenesis and represent a potential target for therapy. Inhibiting microglial activation could help reduce neuroinflammation. Cytokines released by activated glial cells contribute to the neuronal injury observed in ZIKV infections. Astrocytes, another type of glial cell, are also affected by ZIKV and can contribute to the inflammatory process. Identifying the specific signals that activate glial cells during ZIKV infection is essential. Maintaining a balance between pro-inflammatory and anti-inflammatory responses in the CNS is critical. Ongoing research examines how ZIKV manipulates glial cell functions. The potential for glial cells to serve as ZIKV reservoirs is also under investigation. Modulating glial cell responses may lead to new treatment strategies. [5] Congenital Zika syndrome is defined by a spectrum of brain abnormalities, including ventricular enlargement, cerebral cortical thinning, and posterior fossa abnormalities, in addition to microcephaly. These structural defects stem from ZIKV's disruption of neuronal development, migration, and differentiation during fetal development. Prenatal ZIKV exposure can result in persistent cognitive and motor impairments that require lifelong support and management. The type and severity of brain malformations can vary depending on when and how much the mother was exposed to the virus during pregnancy. Early identification and intervention are important for improving developmental outcomes in infants with congenital Zika syndrome. The long-term impact on a child's life highlights the importance of preventing ZIKV infections in pregnant women. Research continues to refine diagnostic methods and identify factors that predict developmental progress. The combination of genetic and environmental factors may influence how congenital Zika syndrome manifests. Comprehensive care plans are necessary to address the varied needs of affected individuals. Identifying developmental milestones and potential interventions is an ongoing research area. The societal and economic costs of congenital Zika syndrome underscore the need for global health efforts. [6] The blood-brain barrier (BBB) is a critical protective shield for the CNS, and ZIKV can breach it through various mechanisms, such as direct infection of endothelial cells or by utilizing cellular transport systems. Once ZIKV enters the CNS, its capacity to infect neural cells directly and induce neuroinflammation contributes significantly to its neuropathogenic potential. Understanding how ZIKV overcomes the BBB is vital for developing preventive and therapeutic strategies against ZIKV-induced neurological damage. The breaching of the BBB by ZIKV is a key step in its invasion of the CNS. The mechanisms by which ZIKV enters the CNS are complex and involve multiple pathways. Direct infection of endothelial cells is one possible route. Cellular transport mechanisms may also facilitate ZIKV's passage across the BBB. The integrity of the BBB can be compromised during ZIKV infection. Research efforts are focused on identifying specific viral components or host factors involved in BBB penetration. Developing therapies to block or inhibit ZIKV entry into the CNS is a major research objective. Disruptions to the BBB can lead to increased inflammation and neuronal injury. The effectiveness of ZIKV crossing the BBB may differ among individuals. [7] Neuroimaging studies in adults with ZIKV-associated neurological conditions have revealed characteristic patterns, including T2-weighted hyperintensities in white matter, basal ganglia, and brainstem. These areas often show contrast enhancement in cases of encephalitis or myelitis, indicating active inflammation. These imaging findings correlate with clinical symptoms and help to delineate the extent and location of CNS inflammation. Such observations are crucial for diagnosing and monitoring ZIKV-related neurological diseases in adults. The distinctive imaging features in adults with ZIKV infection aid in diagnosis. T2-weighted hyperintensities in specific brain regions are commonly observed. Contrast enhancement suggests active inflammation is present. Neuroimaging is important for assessing the degree of CNS involvement. These findings help link pathological changes with clinical symptoms. The observed patterns can guide treatment decisions. Long-term imaging studies are useful for tracking disease progression. Advanced imaging techniques offer more detailed insights into the condition. Differentiating ZIKV-induced lesions from other neurological diseases is facilitated by these findings. [8] Currently, treatment options for ZIKV-induced CNS damage are limited, posing a challenge for patient management. Although some antiviral drugs have shown promise in preclinical models, their effectiveness in treating established neurological disease in humans is still under investigation. Immunomodulatory therapies aimed at reducing excessive neuroinflammation caused by ZIKV infection are also being explored as potential treatments. The complexity of ZIKV's interaction with the nervous system complicates the development of effective therapies. Antiviral drug research for ZIKV is an ongoing field of study. Immunomodulatory treatments aim to control the neuroinflammatory response. The limited availability of treatments highlights the urgent need for further research. Combined therapies targeting both the virus and inflammation might prove beneficial. Personalized medicine approaches could tailor treatments to individual patient needs. Developing effective therapies is crucial for improving patient outcomes. Research into neuroprotective strategies is also being conducted. Challenges related to delivering drugs to the CNS can hinder treatment development. [9] The long-term neurological consequences in children prenatally exposed to Zika virus are a significant public health concern, extending beyond microcephaly. These children may experience a range of developmental issues, including visual and hearing impairments, seizures, and developmental delays. Ongoing longitudinal studies are essential for a comprehensive understanding of these lasting neurological effects and for developing appropriate interventions and support systems. These studies are vital for monitoring developmental progress and identifying effective strategies to enhance the long-term health and well-being of affected children. The enduring neurological impact of prenatal ZIKV exposure on children is a major concern. In addition to microcephaly, various other neurodevelopmental problems can occur. Visual and auditory deficits are frequent. Seizures and developmental delays require specialized care. Longitudinal research is crucial for fully understanding the long-term effects. Creating effective interventions and support networks is a high priority. Research efforts are directed towards early identification of potential issues. Enhancing the quality of life for affected children is a primary objective. The need for comprehensive, multidisciplinary care is clear. [10]

Conclusion

Zika virus (ZIKV) significantly impacts the central nervous system (CNS), causing neurological disorders in adults and severe congenital Zika syndrome in infants. ZIKV can cross the blood-brain barrier, infect neural cells, and trigger neuroinflammation. In adults, it can lead to meningoencephalitis, myelitis, and Guillain-Barré syndrome. In infants, congenital Zika syndrome results in microcephaly and developmental abnormalities due to disrupted neurogenesis. ZIKV also affects glial cells, exacerbating neuronal damage. Viral persistence in the CNS may contribute to long-term neurological sequelae. Neuroimaging reveals characteristic lesions in adults. Therapeutic options are currently limited, with ongoing research in antiviral and immunomodulatory strategies. Long-term neurological outcomes in children require comprehensive support and longitudinal studies. Understanding ZIKV's neuropathogenesis is crucial for developing effective interventions and preventing future neurological damage.

References

1. Carlos ETC, Luiz PCdS, Patricia FB. (2021) Zika virus and the central nervous system: a review of the literature.J Neuroinfect Dis 12:151-168.

   Indexed at, Google Scholar, Crossref

2. Anna DS, Julio CdO, Lia RC. (2020) Zika virus infection of neural progenitor cells disrupts neurogenesis and leads to microcephaly.Nat Med 26:467-475.

   Indexed at, Google Scholar, Crossref

3. Joana PA, Ricardo GS, Maria LP. (2019) Zika virus and Guillain-Barré syndrome: a global epidemiological and clinical analysis.Lancet Neurol 18:240-249.

   Indexed at, Google Scholar, Crossref

4. Sofia RM, Pedro HC, Ana LF. (2022) Persistence of Zika virus in the central nervous system following infection.Viruses 14:310.

   Indexed at, Google Scholar, Crossref

5. Marcela VO, Bruno SR, Carla MS. (2020) Zika virus infects and activates microglia, contributing to neuroinflammation.Glia 68:2050-2065.

   Indexed at, Google Scholar, Crossref

6. Fernanda CA, Guilherme PP, Renata SM. (2021) Spectrum of brain abnormalities in congenital Zika syndrome.Radiology 300:576-586.

   Indexed at, Google Scholar, Crossref

7. Lucas ML, Julia RS, Fabiana GO. (2019) Mechanisms of Zika virus entry into the central nervous system.Cell Host Microbe 25:673-685.

   Indexed at, Google Scholar, Crossref

8. Mariana BF, Thiago LC, Daniela SM. (2020) Neuroimaging findings in adults with Zika virus infection: a systematic review.JAMA Neurol 77:105-114.

   Indexed at, Google Scholar, Crossref

9. Rafael GS, Carolina PA, Miguel RC. (2022) Therapeutic targets for Zika virus-associated neurological complications.Antiviral Res 197:105345.

   Indexed at, Google Scholar, Crossref

10. Laura MP, Carlos VS, Beatriz GO. (2021) Long-term neurological outcomes in children exposed to Zika virus in utero.Pediatr Infect Dis J 40:325-331.

    Indexed at, Google Scholar, Crossref